Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Eun-Ju Ko & Sang-Moo Kang. (2018) Immunology and efficacy of MF59-adjuvanted vaccines. Human Vaccines & Immunotherapeutics 14:12, pages 3041-3045.
Read now
Read now
Claudia Maria Trombetta, Elena Gianchecchi & Emanuele Montomoli. (2018) Influenza vaccines: Evaluation of the safety profile. Human Vaccines & Immunotherapeutics 14:3, pages 657-670.
Read now
Read now
Claudia Maria Trombetta & Emanuele Montomoli. (2016) Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Review of Vaccines 15:8, pages 967-976.
Read now
Read now
Nagendra R Hegde. (2015) Cell culture-based influenza vaccines: A necessary and indispensable investment for the future. Human Vaccines & Immunotherapeutics 11:5, pages 1223-1234.
Read now
Read now
Articles from other publishers (17)
Jiang Qian, Matthew P. Donohue, Thomas Bowen & Ying Zhang. (2023) The CombE-IDMS Assay as an Alternate Potency Method for Adjuvanted Quadrivalent Influenza Vaccines. Analytical Chemistry 95:34, pages 12842-12850.
Crossref
Crossref
Kristopher K. Short, Stephanie K. Lathrop, Clara J. Davison, Haley A. Partlow, Johnathan A. Kaiser, Rebekah D. Tee, Elizabeth B. Lorentz, Jay T. Evans & David J. Burkhart. (2022) Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine. Pharmaceutics 14:7, pages 1455.
Crossref
Crossref
Akane Watanabe, Sumiyuki Nishida, Temizöz Burcu, Takayuki Shibahara, Takato Kusakabe, Etsushi Kuroda, Ken J. Ishii & Atsushi Kumanogoh. (2022) Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: A phase 1 clinical trial. Vaccine 40:31, pages 4150-4159.
Crossref
Crossref
Eve Versage, Esther van Twuijver, Wim Jansen, Ad Theeuwes, Daphne Sawlwin & Matthew Hohenboken. (2021) Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults. Vaccines 9:12, pages 1468.
Crossref
Crossref
Patricia Winokur, Hana M. El Sahly, Mark J. Mulligan, Sharon E. Frey, Richard Rupp, Evan J. Anderson, Kathryn M. Edwards, David I. Bernstein, Kenneth Schmader, Lisa A. Jackson, Wilbur H. Chen, Heather Hill & Abigail Bellamy. (2021) Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. Vaccine 39:8, pages 1339-1348.
Crossref
Crossref
N. A. Alpatova, Zh. I. Avdeeva, S. L. Lysikova, O. V. Golovinskaya & L. A. Gayderova. (2020) General Characteristics of Adjuvants and Their Mechanism of Action (Part 1). BIOpreparations. Prevention, Diagnosis, Treatment 20:4, pages 245-256.
Crossref
Crossref
Fatima Laher, Zoe Moodie, Kristen W. Cohen, Nicole Grunenberg, Linda-Gail Bekker, Mary Allen, Nicole Frahm, Nicole L. Yates, Lynn Morris, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Kevin Saunders, Shannon Grant, Chenchen Yu, Peter B. Gilbert, Sanjay Phogat, Carlos A. DiazGranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Carter Bentley, Nonhlanhla N. Mkhize, Michael N. Pensiero, Vijay L. Mehra, James G. Kublin, Lawrence Corey, David C. Montefiori, Glenda E. Gray, M. Juliana McElrath & Georgia D. Tomaras. (2020) Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLOS Medicine 17:2, pages e1003038.
Crossref
Crossref
Xiaoying Shen, Fatima Laher, Zoe Moodie, Arthur S. McMillan, Rachel L. Spreng, Peter B. Gilbert, Ying Huang, Nicole L. Yates, Nicole Grunenberg, M. Juliana McElrath, Mary Allen, Michael Pensiero, Vijay L. Mehra, Olivier Van Der Meeren, Susan W. Barnett, Sanjay Phogat, Glenda E. Gray, Linda-Gail Bekker, Lawrence Corey & Georgia D. Tomaras. (2020) HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. Scientific Reports 10:1.
Crossref
Crossref
Etsuro Nanishi, David J. Dowling & Ofer Levy. (2020) Toward precision adjuvants: optimizing science and safety. Current Opinion in Pediatrics 32:1, pages 125-138.
Crossref
Crossref
Jing Yang, Jiayou Zhang, Tian Han, Chen Liu, Xinghang Li, Luyao Yan, Baifeng Yang & Xiaoming Yang. (2020) Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups. Medicine 99:7, pages e19095.
Crossref
Crossref
Pornthep Chanthavanich, Edwin Anderson, Phirangkul Kerdpanich, Michael BulittaNiranjan Kanesa-thasan & Matthew Hohenboken. (2019) Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects. Pediatric Infectious Disease Journal 38:7, pages 757-764.
Crossref
Crossref
Michael I. Hauser, David J. Muscatello, Annabel C.Y. Soh, Dominic E. Dwyer & Robin M. Turner. (2019) An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines. Vaccine 37:31, pages 4246-4255.
Crossref
Crossref
Sharon E Frey, Sepehr Shakib, Pornthep Chanthavanich, Peter Richmond, Timothy Smith, Terapong Tantawichien, Claudia Kittel, Peter Jaehnig, Zenaida Mojares, Bikash Verma, Niranjan Kanesa-thasan & Matthew Hohenboken. (2019) Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly. Open Forum Infectious Diseases 6:4.
Crossref
Crossref
Alejandro Ramirez, Mary Co & Anuja Mathew. (2016) CpG Improves Influenza Vaccine Efficacy in Young Adult but Not Aged Mice. PLOS ONE 11:3, pages e0150425.
Crossref
Crossref
Nuriban Valero-Pacheco, Marisol Pérez-Toledo, Miguel Ángel Villasís-Keever, Adriana Núñez-Valencia, Ilka Boscó-Gárate, Bernardo Lozano-Dubernard, Horacio Lara-Puente, Clara Espitia, Celia Alpuche-Aranda, Laura C. Bonifaz, Lourdes Arriaga-Pizano, Rodolfo Pastelin-Palacios, Armando Isibasi & Constantino López-Macías. (2016) Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine. PLOS ONE 11:2, pages e0150146.
Crossref
Crossref
Nicos KarasavvasChitraporn KarnasutaHathairat SavadsukSirinan MadnoteDutsadee InthawongSomsak ChantakulkijSurawach RittiroongradSorachai NitayaphanPunnee PitisuttithumPrasert ThongcharoenVinai SiriyanonCharla A. AndrewsSusan W. BarnettJames TartagliaFaruk SinangilDonald P. FrancisMerlin L. RobbNelson L. MichaelViseth NgauyMark S. de SouzaRobert M. ParisJean-Louis ExclerJerome H. KimRobert J. O'Connell. (2015) IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. AIDS Research and Human Retroviruses 31:11, pages 1178-1186.
Crossref
Crossref
Ryo Arakane, Hitomi Nakatani, Emi Fujisaki, Akiko Takahama, Katsuyasu Ishida, Michiharu Yoshiike, Tetsuo Nakayama & Fumihiko Takeshita. (2015) Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial. Vaccine 33:46, pages 6340-6350.
Crossref
Crossref